Athersys, Inc.
United States
Athersys is committed to scientific excellence, helping patients and developing safer and more effective therapies to address unmet medical needs to extend and enhance human life.
329 articles about Athersys, Inc.
-
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
3/31/2023
Athersys, Inc. announced financial results for the three and 12 months ended December 31, 2022, and provided a business update.
-
Athersys Announces Successful Type B Meeting with the FDA
3/22/2023
Athersys, Inc. announced planned amendments to its MASTERS-2 clinical trial protocol following a Type B meeting with the U.S. Food & Drug Administration (FDA).
-
Athersys Expands IP Protection with First New Patent for SIFU® Technology
2/28/2023
Athersys, Inc. announced today that the United States Patent and Trademark Office has granted the Company a new patent for its novel cryogenic storage system.
-
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
2/14/2023
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the Company has been granted a clinical Type B meeting with the U.S. Food & Drug Administration (FDA).
-
Athersys to Host Business Update Conference Call on February 14th
2/2/2023
Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time.
-
Athersys to Participate in International Stroke Conference and BioProcess International
1/30/2023
Athersys, Inc. announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in Houston, TX and BioProcess International US West from February 27-March 2, 2023 in San Diego, CA.
-
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
1/11/2023
Athersys, Inc. (NASDAQ: ATHX) announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK.
-
Athersys Provides MultiStem Clinical Update
1/9/2023
Athersys, Inc. today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).
-
Athersys Appoints Joseph Nolan to Its Board of Directors
1/5/2023
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023.
-
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
11/15/2022
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and nine months ended September 30, 2022 and provided a business update.
-
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference
11/11/2022
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.’s Biotech Conference on November 30, 2022.
-
Athersys Reschedules Third Quarter Conference Call to November 15
11/10/2022
Athersys, Inc. announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securities and Exchange Commission (SEC) after market close on Monday, November 14, 2022, issue a news release reporting those financial results and recent business highlights before market open on Tuesday, November 15, 2022, and hold a conference call at 11:00 a.m. Eastern Time on Tuesday, November 15, 2022.
-
Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
11/10/2022
Athersys, Inc. announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of the Company’s common stock and warrants to purchase up to 10,009,090 of common stock at a combined purchase price of $1.10, resulting in gross proceeds of approximately $5.5 million before deducting placement agent fees and other offering expenses.
-
Athersys, Inc. Announces Pricing of $5.5 Million Public Offering
11/9/2022
Athersys, Inc. announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of common stock and warrants to purchase 10,009,090 shares of common stock at a combined price of $1.10 per share and accompanying warrant for aggregate gross proceeds of approximately $5.5 million, before deducting placement agent fees and other offering expenses.
-
Athersys, Inc. Announces Proposed Public Offering - November 07, 2022
11/7/2022
Athersys, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock, subject to market and other conditions, in a public offering.
-
Athersys to Host Third Quarter 2022 Financial Results Call
10/25/2022
Athersys, Inc. will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results. Members of the management team will host the call as follows: Date November 10, 2022 Time 4:30 p.m.
-
Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October
10/4/2022
Athersys, Inc. announced today their participation in two October conferences, the 2022 Cell & Gene Meeting on the Mesa on October 11-13, 2022 and the 14th World Stroke Congress on October 26-29, 2022.
-
Athersys to Host Business Update Conference Call on October 6th
9/30/2022
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time.
-
Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering
9/23/2022
Athersys, Inc. announced today that it has entered into amended agreements to extend the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022, among other changes, and to issue additional warrants to the same warrant holder, a healthcare-focused U.S. institutional investor.
-
Athersys Announces 1-for-25 Reverse Stock Split
8/25/2022
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 after the close of trading on the Nasdaq Stock Market on Friday, August 26, 2022.